BIOMAT Database Logo BIOMAT Database Logo

Animal model for immune dysfunction associated with adenosine deaminase deficiency. 1980

A Tedde, and M E Balis, and S Ikehara, and R Pahwa, and R A Good, and P P Trotta

An in vivo murine model for immunodeficiency of both B and T cells is produced by continuous intraperitoneal infusion of 2'-deoxycoformycin (DCF), a specific tightly binding inhibitor of adenosine deaminase (ADase; adenosine aminohydrolase, EC 3.5.4.4). After DCF infusion, ADase of thymus, spleen, and lymph nodes was inhibited to varying degrees ranging from 57% to 100%. Immunodeficiency under these conditions was indicated by: (i) a striking decrease in lymphocyte response to the T-cell mitogens concanavalin A and phytohemagglutinin; (ii) an impairment of delayed hypersensitivity measured by the footpad reaction; (iii) a decrease in antibody production measured in both in vivo and in vitro plaque-forming cell assay; (iv) a significant prolongation of mouse skin allograft survival after transplantation into the C57BL/6J (H-2b) strain of skin from BALB/c (H-2d) mice; and (v) a marked lymphopenia. Histological examination indicated lymphoid degeneration in the thymus, lymph nodes, and spleen with no alterations in other tissues including bone marrow, kidney, lung, gastrointestinal tract, and liver except for the occurrence of hepatitis. A decrease in the number of Thy-1-positive cells in both spleen and lymph nodes further supported the fact of cytotoxicity of DCF to T cells. Anorexia and weight loss were observed within 5 days of continuous DCF infusion at 0.4 mg/kg body weight per day. These data indicate that this method provides an experimental model for future studies on the biochemical mechanisms responsible for the genetically determined severe combined immunodeficiency disease in man.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007153 Immunologic Deficiency Syndromes Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral. Antibody Deficiency Syndrome,Deficiency Syndrome, Immunologic,Deficiency Syndromes, Antibody,Deficiency Syndromes, Immunologic,Immunologic Deficiency Syndrome,Immunological Deficiency Syndromes,Antibody Deficiency Syndromes,Deficiency Syndrome, Antibody,Deficiency Syndrome, Immunological,Deficiency Syndromes, Immunological,Immunological Deficiency Syndrome,Syndrome, Antibody Deficiency,Syndrome, Immunologic Deficiency,Syndrome, Immunological Deficiency,Syndromes, Antibody Deficiency,Syndromes, Immunologic Deficiency,Syndromes, Immunological Deficiency
D009700 Nucleoside Deaminases Catalyze the hydrolysis of nucleosides with the elimination of ammonia. Deaminases, Nucleoside
D003070 Coformycin A ribonucleoside antibiotic synergist and adenosine deaminase inhibitor isolated from Nocardia interforma and Streptomyces kaniharaensis. It is proposed as an antineoplastic synergist and immunosuppressant.
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000241 Adenosine A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Adenocard,Adenoscan
D000243 Adenosine Deaminase An enzyme that catalyzes the hydrolysis of ADENOSINE to INOSINE with the elimination of AMMONIA. Adenosine Aminohydrolase,Aminohydrolase, Adenosine,Deaminase, Adenosine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D001402 B-Lymphocytes Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent

Related Publications

A Tedde, and M E Balis, and S Ikehara, and R Pahwa, and R A Good, and P P Trotta
Metabolic basis for immune dysfunction in adenosine deaminase deficiency.
January 1985, Annals of the New York Academy of Sciences,
A Tedde, and M E Balis, and S Ikehara, and R Pahwa, and R A Good, and P P Trotta
Purine dysfunction in cells from patients with adenosine deaminase deficiency.
July 1976, Pediatric research,
A Tedde, and M E Balis, and S Ikehara, and R Pahwa, and R A Good, and P P Trotta
[Adenosine deaminase activity and immune dysfunction (author's transl)].
January 1981, Allergie und Immunologie,
A Tedde, and M E Balis, and S Ikehara, and R Pahwa, and R A Good, and P P Trotta
A case of osteoporosis associated with adenosine deaminase deficiency.
September 1990, Italian journal of orthopaedics and traumatology,
A Tedde, and M E Balis, and S Ikehara, and R Pahwa, and R A Good, and P P Trotta
[Adenosine deaminase deficiency].
January 1998, Ryoikibetsu shokogun shirizu,
A Tedde, and M E Balis, and S Ikehara, and R Pahwa, and R A Good, and P P Trotta
Adenosine deaminase deficiency.
June 1987, Hospital practice (Office ed.),
A Tedde, and M E Balis, and S Ikehara, and R Pahwa, and R A Good, and P P Trotta
[Adenosine deaminase deficiency].
January 2000, Ryoikibetsu shokogun shirizu,
A Tedde, and M E Balis, and S Ikehara, and R Pahwa, and R A Good, and P P Trotta
Adenosine deaminase deficiency.
January 1990, Immunodeficiency reviews,
A Tedde, and M E Balis, and S Ikehara, and R Pahwa, and R A Good, and P P Trotta
[Adenosine deaminase deficiency].
May 1978, Nihon rinsho. Japanese journal of clinical medicine,
A Tedde, and M E Balis, and S Ikehara, and R Pahwa, and R A Good, and P P Trotta
[Adenosine deaminase deficiency].
January 2001, Ryoikibetsu shokogun shirizu,
Copied contents to your clipboard!